MindMed begins phase 3 study of MM120 for anxiety disorder
First patient dosed in landmark trial for GAD treatment MindMed has announced the dosing of the first patient in its...
Selected News
German cancer centre treats first patient with Elekta Evo
New CT-guided radiotherapy system offers personalised cancer treatment Berlin’s Diagnostisch Therapeutisches Zentrum (DTZ) has become the first in the world...
Bayer begins inhibitor study treating advanced KRAS-mutated tumours
Trial explores potential of therapy in treating multiple cancer types Bayer has begun a phase 1 clinical trial for BAY3498264,...
Leriglitazone meets primary endpoint in pivotal cALD trial
Promising trial results support marketing authorisation application Minoryx Therapeutics and Neuraxpharm Group have announced that leriglitazone has met the primary...
iOnctura achieves new clinical milestones in uveal melanoma therapy
Successful phase 1 study highlights potential of roginolisib iOnctura has announced promising results from the phase 1 DIONE-01 study, showcasing...
Leriglitazone meets endpoint in trial for cerebral adrenoleukodystrophy
Promising results set stage for European marketing authorization Minoryx Therapeutics and Neuraxpharm Group have announced that leriglitazone met the primary...
Cellenkos presents promising phase 1b data for CK0804 in myelofibrosis
New cell therapy shows potential in treating advanced blood disorder Cellenkos has unveiled new phase 1b data for its T-regulatory...
CatalYm shows potential of visugromab for treating cachexia
New findings presented at international SCWD conference CatalYm has announced promising new data on its lead drug candidate, visugromab, at...
Imfinzi receives NICE recommendation for lung cancer treatment
Trial results lead to new treatment option for lung cancer AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended...
Poolbeg Pharma presents positive results for POLB 001
promising pre-clinical data on preventing cytokine release syndrome Poolbeg Pharma has unveiled encouraging pre-clinical study data for POLB 001 at...
Teva’s Ajovy shows positive results in preventing pediatric migraines
Phase 3 trial indicates significant efficacy and safety for children and adolescents Teva Pharmaceutical Industries has presented positive data from...
NICE endorses Neuraxpharm’s ublituximab for treating MS
New antibody therapy shows promise in managing condition Neuraxpharm Group has announced that the National Institute for Health and Care...
Antag Therapeutics secures €80 million in weight loss therapy financing
Versant Ventures leads investment round to advance drug Antag Therapeutics has announced the closing of an €80 million Series A...
Everest therapy shows promise in nephropathy trial
Data highlights effectiveness of EVER001 in treating pMN Everest Medicines has announced promising results from the Phase 1b/2a clinical trial...
KIMMTRAK recommended for funding by NICE for uveal melanoma patients
Immunocore has announced that Kimmtrak (tebentafusp) has been recommended for funding in England by the National Institute for Health and...
Orbit Discovery and Evergreen Theragnostics expand research collaboration
Partnership aims to develop new radiopharmaceuticals for cancer treatment Orbit Discovery, based in Oxford, UK, and Evergreen Theragnostics, headquartered in...
OGT launches enhanced genetic profiling panel for CLL
New SureSeq CLL + CNV V3 panel improves understanding of CLL OGT has announced the launch of its enhanced SureSeq...
Pharma giants vie for oral GLP-1R approval
Race to create first oral drug for obesity intensifies The competition to gain approval for the first oral GLP-1R drug...
New injection offers hope for asthma and COPD attacks
Injection significantly reduces need for further treatment A new treatment for asthma and COPD attacks could revolutionise patient care, scientists...
UK grants promising innovative medicine status to CIDP drug
Therapy for autoimmune disorder shows potential Argenx’s investigational therapy, subcutaneous efgartigimod alfa, has been granted Promising Innovative Medicine (PIM) status...
